Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase II extension study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells inn pediatric patients affected by hematological disorders

Proposed period of release:
01/07/2017 to 01/07/2019

Name of the Institute(s) or Company(ies)
Bellicum Pharmaceuticals, Inc., 2130 West Holcombe Blvd, Houston
Texas, 77030 USA;

3. Is the same GMO release planned elsewhere in the Community?
United Kingdom; Italy;

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
T cells obtained from haploidentical donor
- Genus: Homo
- Species: Homo Sapiens

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known